Drug Trial Radar · NCT04708314
An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Oct 31, 2020
Primary completion
May 13, 2021
Study completion May 13, 2021
Sponsor
- Lead sponsor
- Rare Disease Research, LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sarepta Therapeutics, Inc.
- First posted
- Jan 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study to evaluate the safety and tolerability of golodirsen injection in Non-ambulant DMD patients with confirmed genetic mutations amenable to treatment by exon 53 skipping (Golodirsen). Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study. Safety will be regularly assessed throughout the study via the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations. Exploratory assessments, including pulmonary function tests (PFTs), upper extremity testing, and other measurements of functional status, will occur at functional assessment visits every 12 weeks over the first year of treatment and approximately every 24 weeks over the second year of treatment.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]Drug
Vyondys 53
Primary outcomes
What the sponsor says the trial is designed to measure.
- Explore the safety and tolerability of Golodirsen in number of participants with Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to 96 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rare Disease Research, LLC
Atlanta, Georgia
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.